tradingkey.logo

Rapid Micro Biosystems Inc

RPID
查看详细走势图
3.200USD
+0.050+1.59%
交易中 美东报价延迟15分钟
141.79M总市值
亏损市盈率 TTM

Rapid Micro Biosystems Inc

3.200
+0.050+1.59%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.59%

5天

-12.09%

1月

-23.26%

6月

-3.61%

今年开始到现在

+255.56%

1年

+255.56%

查看详细走势图

TradingKey Rapid Micro Biosystems Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Rapid Micro Biosystems Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名117/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价8.00。中期看,股价处于平稳状态。近一个月,市场表现非常差,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Rapid Micro Biosystems Inc评分

相关信息

行业排名
117 / 208
全市场排名
278 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 4 位分析师
买入
评级
8.000
目标均价
+101.01%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Rapid Micro Biosystems Inc亮点

亮点风险
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
业绩高增长
公司营业收入稳步增长,连续3年增长63.72%
业绩增长期
公司处于发展阶段,最新年度总收入28.05M美元
估值低估
公司最新PE估值-3.16,处于3年历史低位
机构减仓
最新机构持股23.72M股,环比减少6.05%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值965.02K

Rapid Micro Biosystems Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Rapid Micro Biosystems Inc简介

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
公司代码RPID
公司Rapid Micro Biosystems Inc
CEOSpignesi (Robert)
网址https://www.rapidmicrobio.com/

常见问题

Rapid Micro Biosystems Inc(RPID)的当前股价是多少?

Rapid Micro Biosystems Inc(RPID)的当前股价是 3.200。

Rapid Micro Biosystems Inc的股票代码是什么?

Rapid Micro Biosystems Inc的股票代码是RPID。

Rapid Micro Biosystems Inc股票的52周最高点是多少?

Rapid Micro Biosystems Inc股票的52周最高点是4.500。

Rapid Micro Biosystems Inc股票的52周最低点是多少?

Rapid Micro Biosystems Inc股票的52周最低点是0.870。

Rapid Micro Biosystems Inc的市值是多少?

Rapid Micro Biosystems Inc的市值是141.79M。

Rapid Micro Biosystems Inc的净利润是多少?

Rapid Micro Biosystems Inc的净利润为-46.89M。

现在Rapid Micro Biosystems Inc(RPID)的股票是买入、持有还是卖出?

根据分析师评级,Rapid Micro Biosystems Inc(RPID)的总体评级为买入,目标价格为8.000。

Rapid Micro Biosystems Inc(RPID)股票的每股收益(EPS TTM)是多少

Rapid Micro Biosystems Inc(RPID)股票的每股收益(EPS TTM)是-0.998。
KeyAI